The Global Plasma Protein Therapeutics Market Size is estimated to be at USD 23935.47 Million in 2018 and is poised to reach USD 36777.04 Million by 2023 with a CAGR of 8.97%. The use of plasma protein in the medical applications has increased significantly in the recent years. With the advancements in technology, the process for fractionating the protein from plasma has become more cost saving and efficient and is supposed to boost the plasma protein therapeutics market. According to WHO reports more than half of the global blood donors belong to high income countries which constitutes 18% of the population. With rising awareness among people regarding blood donations and government initiatives, plasma derived medicine market is expected to grow at a significant rate in the coming years.
Plasma Protein Therapeutics Industry overview
Plasma is a protein rich fluid and plays a crucial role in clotting and providing immunity to diseases. By isolating the proteins from plasma, they can used for medical therapies including autoimmune, immune deficiencies, neurological and bleeding disorders. Plasma protein therapies are used to treat well-defined medical condition by replacing the deficient or missing proteins in plasma. Plasma protein therapeutics involves biological medicines either infused or injected to treat life-threatening, chronic and genetic diseases.
Increasing introduction of new plasma-derived therapies is the primary driving factor for the market. The market is also driven by a host of other factors, including rising prevalence of life threatening diseases involving immune or neurological systems and other infectious diseases like Rabies, Tetanus, Hepatitis A&B and varicella. On the contrary there are a few restraints for market which includes stringent government policies, issues pertaining to reimbursement, complexity in manufacturing.
Plasma Protein Therapeutics Industry segment-level analysis
The Global Plasma Protein Therapeutics Market is segmented based on product type as Immunoglobulins, Albumin, Coagulation Factors, alpha-1 proteinase inhibitor and others. On the basis of application the market is categorised as Hemophilia, Primary Immunodeficiency Disorder, Idiopathic Thrombocytopenic Purpura, Secondary Immunodeficiency and others. Based on geographical region, the market is analysed in the regions of North America, Europe, Asia-Pacific, Latin America and Middle-East & Africa.
The major players in the plasma protein therapeutic market are Baxter, CSL Behring, Biotest, China Biologics, Grifols, Kedrion, Octapharma, Shire Plc., and Chengdu Inst.
1. Introduction
1.1 Market Definition
1.2 Study Deliverables
1.3 Base Currency, Base Year and Forecast Periods
1.4 General Study Assumptions
2. Research Methodology
2.1 Introduction
2.2 Research Phases
2.2.1 Secondary Research
2.2.2 Primary Research
2.2.3 Econometric Modelling
2.2.4 Expert Validation
2.3 Analysis Design
2.4 Study Timeline
3. Overview
3.1 Executive Summary
3.2 Key Inferences
3.3 New Developments
4. Drivers, Restraints, Opportunities, and Challenges Analysis (DROC)
4.1 Market Drivers
4.2 Market Restraints
4.3 Key Challenges
4.4 Current Opportunities in the Market
5. Market Segmentation
5.1 By Type
5.1.1 Immunoglobulins
5.1.2 Albumin
5.1.3 Coagulation Factors
5.1.4 Alpha-1 proteinase inhibitor
5.1.5 Others
5.2 By Application
5.2.1 Hemophilia
5.2.2 Primary Immunodeficiency Disorder
5.2.3 Idiopathic Thrombocytopenic Purpura
5.2.4 Secondary Immunodeficiency
5.2.5 Others
6. Geographical Analysis
6.1 North America
6.1.1 Introduction
6.1.2 United States
6.1.3 Canada
6.2 Europe
6.2.1 Introduction
6.2.2 U.K
6.2.3 Spain
6.2.4 Germany
6.2.5 Italy
6.2.6 France
6.3 Asia-Pacific
6.3.1 Introduction
6.3.2 China
6.3.3 India
6.3.4 Japan
6.3.5 South Korea
6.3.6 Australia
6.4 Latin America
6.4.1 Introduction
6.4.2 Brazil
6.4.3 Mexico
6.4.4 Rest of Latin America
6.5 Middle East & Africa
6.5.1 Introduction
6.5.2 Middle-East
6.5.3 Africa
7. Strategic Analysis
7.1 PESTLE analysis
7.1.1 Political
7.1.2 Economic
7.1.3 Social
7.1.4 Technological
7.1.5 Legal
7.1.6 Environmental
7.2 Porter’s Five analysis
7.2.1 Bargaining Power of Suppliers
7.2.2 Bargaining Power of Consumers
7.2.3 Threat of New Entrants
7.2.4 Threat of Substitute Products and Services
7.2.5 Competitive Rivalry within the Industry
8. Market Leaders' Analysis
8.1 CSL Behring
8.1.1 Overview
8.1.2 Product Analysis
8.1.3 Strategic Evaluation and Operations
8.1.4 Financial analysis
8.1.5 Legal issues
8.1.6 Recent Developments
8.1.7 SWOT analysis
8.1.8 Analyst View
8.2 Baxter
8.3 Biotest
8.4 China Biologics
8.5 Grifols
8.6 Kedrion
8.7 Octapharma
8.8 Shire Plc.
8.9 Chengdu Inst.
9. Competitive Landscape
9.1 Market share analysis
9.2 Merger and Acquisition Analysis
9.3 Agreements, collaborations and Joint Ventures
9.4 New Product Launches
10. Expert Opinions
10.1 Market Outlook
10.2 Investment Opportunities
Appendix
a) List of Tables
b) List of Figures
